Beijing Biostar Pharmaceuticals Co., Ltd.

Room 310, 3/F, Building 3, Courtyard 88, Kechuang Sixth Street, Beijing ETDZ, Beijing, 北京市, China

Clinical Trials

6 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 2

60.0%

Phase 3

26.7%

Phase 1

13.3%

Trial Status Distribution

Active, not recruiting

6.7%

Completed

20.0%

Not yet recruiting

33.3%

Recruiting

33.3%

Suspended

6.7%

Clinical Trials

Trials sponsored by this organization (15)

Utidelone Capsules Combined With Doxorubicin for Advanced Soft Tissue Sarcoma

Phase 2

Not yet recruiting

interventional

Oct 202649 participants

Efficacy and Safety of Utidelone Capsule and Utidelone Injection in Patients With HER-2 Negative Advanced Breast Cancer

Phase 3

Not yet recruiting

interventional

Aug 2026308 participants

Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2

Not yet recruiting

interventional

Sep 202572 participants

Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma

Phase 2

Recruiting

interventional

Aug 2025778 participants

A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

Phase 2

Recruiting

interventional

Jul 2025120 participants

Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases

Phase 2

Not yet recruiting

interventional

Dec 2024118 participants

Utidelone Capsule Monotherapy for Patients with Advanced Solid Tumors

Phase 2

Not yet recruiting

interventional

Dec 2024100 participants

Phase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid Tumors

Phase 1

Active, not recruiting

interventional

Jun 202384 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

Back to Organizations